Apogee Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | $-255.8M | $-182.1M | $-84.0M | $-39.8M |
| Depreciation & Amortization | — | — | — | — |
| Depreciation | $1.4M | $189.0K | — | — |
| Amortization | — | — | — | — |
| Stock-Based Compensation | $46.3M | $23.3M | $6.1M | $2.1M |
| Net Cash from Operating Activities | $-227.5M | $-171.2M | $-74.8M | $-16.4M |
| Investing Activities | ||||
| Capital Expenditures | $5.1M | $1.2M | $167.0K | — |
| Business Acquisitions | — | — | — | — |
| Net Cash from Investing Activities | $-179.6M | $-300.5M | $-273.9M | — |
| Financing Activities | ||||
| Dividends Paid | — | — | — | — |
| Stock Repurchases | — | — | — | — |
| Net Cash from Financing Activities | $396.5M | $495.1M | $315.4M | $168.3M |
| Net Change in Cash | $-10.5M | $23.5M | $-33.3M | $151.9M |
| Free Cash Flow | $-232.6M | $-172.3M | $-74.9M | — |